Metadichol was reported last year as being effective for Type 1 and Type 2 diabetes in case studies.  Two issues for diabetes are insulin resistance and obesity.  A target that is now being researched for metabolic disease is GPR-120.  In research by others, GPR-120 agonist has been found effective in anti-inflammatory, insulin sensitization, and anti-obesity effects.  Metadichol has been found as a GPR-120 agonist.

The paper, Metadichol® A Novel Nano Lipid; GPR-120 Agonist, reaches the conclusion that: “Metadichol has the potential to serve in mitigating diabetes with a broad spectrum of activity and with a safety that with [of]no toxicity at doses of up to 5000 mg/kg [20-22]. Metadichol is a far [more] effective substitute to prescription drugs, which have been largely ineffective in diabetes and have many side effects that add to health care costs.”

Here is a link for you to download the paper: GPR-120 Agonist Metadichol

Mark Pegram

Citation: Raghavan P.R. Metadichol® A Novel Nano Lipid; GPR 120 Agonist. Int J Diabetes Complications. 2017; 1-3.

A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice.   Nat Med. 2014 Aug;20(8):942-7. doi: 10.1038/nm.3614. Epub 2014 Jul 6  https://www.ncbi.nlm.nih.gov/pubmed/24997608